Showing results (71-80 of 153) with videos related to
Sort By:
Pageof 16
Journal for Immunotherapy of Cancer|August 27, 2020
HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug deliverySteven C Katz, Ashley E Moody, Prajna Guha, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 28, 2024
Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated CytotoxicityZachary L Z Hay, Dale D Kim, Jennifer M Cimons, et al.Nature Communications|October 23, 2022
Epigenetic control of chromosome-associated lncRNA genes essential for replication and stabilityMichael B Heskett, Athanasios E Vouzas, Leslie G Smith, et al.Biorxiv : the Preprint Server for Biology|September 2, 2025
Autosomal Allelic Inactivation: Variable Replication and Dosage SensitivityMichael B Heskett, Athanasios E Vouzas, Brian Johnstone, et al.Elife|July 8, 2026
Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivityMichael B Heskett, Athanasios E Vouzas, Brian Johnstone, et al.Cell Cycle (Georgetown, Tex.)|December 24, 2015
ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer originDaria Fleyshman, Peter Cheney, Anda Ströse, et al.Nature Communications|May 14, 2016
Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumoursSuzanne S Fei, Asia D Mitchell, Michael B Heskett, et al.Gynecologic Oncology|May 11, 2026
Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventyEliya Shachar, Gilat Rotkop, Roni Haas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2020
The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free IntervalKimberly R Jordan, Matthew J Sikora, Jill E Slansky, et al.Plos One|August 29, 2015
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary DiseaseTimothy M Butler, Katherine Johnson-Camacho, Myron Peto, et al.Pageof 16